Can you take Omeprazole in the morning and Famotidine at night?
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
In this article, we will discuss the use of Omeprazole in the morning and Famotidine at night. We will also discuss the potential benefits and risks of this combination.
Can you take Omeprazole in the morning and Famotidine at night?
Yes, you can take Omeprazole in the morning and Famotidine at night. Omeprazole is a proton pump inhibitor which controls stomach acid secretion (1).
Famotidine, on the other hand, is an H2 receptor blocker which also manages stomach acidity (2). Taking these two medications on the same day is absolutely okay and there are no known interactions between them.
It’s common for people to take more than one acid reducer for managing acidic reflux throughout the day. However, each individual is different and could have different factors contributing to increased acid reflux.
This is why it’s important to talk to your doctor about your acid reflux and rule out conditions like ulcers.
Potential benefits of taking Omeprazole in the morning and Famotidine at night
Taking Omeprazole in the morning and Famotidine at night can help with stomach issues. When you take Omeprazole before breakfast, it works best because it stops your stomach from making too much acid (1).
This is important because when you have an empty stomach, the medicine is absorbed better. By blocking the pump that makes acid, Omeprazole keeps your stomach from producing too much acid when you eat (1).
Now, let’s talk about Famotidine at night. When you take Famotidine before your evening meal or before bedtime, it helps protect you from acid troubles at night (3,4).
This is especially useful because when you lie down to sleep, your stomach can produce more acid, which can flow back into your throat and cause discomfort.
Famotidine at night reduces stomach acid while you sleep (3,4). This not only gives relief from nighttime acid problems but also lets you sleep better without being woken up by acid troubles. So, using both of these medicines can give you all-around relief from acid issues.
Potential risks of taking Omeprazole in the morning and Famotidine at night
There are no known potential risks associated with taking Omeprazole in the morning and Famotidine at night. The two medications are not known to interact with one another. However, people may experience side effects specific to each of the medications.
Common side effects may include headache, nausea, diarrhoea, or dizziness, etc. these side effects are not that commonly experienced and these meds are generally well tolerated (1,2). However, chronic use of these meds may cause some mild long-term side effects.
Just make sure you’re not allergic to these medications. If you are or have never used it before, it is important to look out for symptoms like redness, itchiness, swelling, difficulty breathing, etc. It is crucial to seek immediate medical attention if any such symptom shows up.
What to do if your acid reflux does not get better after using Omeprazole and Famotidine?
If your acid reflux does not resolve after taking Omeprazole in the morning and Famotidine at night, it’s important to seek medical attention. Acid reflux can have multiple causes, like an H-pylori infection, which should be diagnosed properly (5).
If your acid reflux is persistent, your doctor may recommend some diagnostic tests to rule out any underlying disease. If your acid reflux has a root cause, your doctor will provide a proper prescription to help your condition.
Chronic acid reflux can damage your stomach and can increase the risk of gastrointestinal bleeding. This is why acid reflux should never be ignored or left untreated.
Conclusion
In this article, we have discussed the potential risks and benefits of taking Omeprazole in the morning and Famotidine at night. We have also discussed that these meds are not known to interact with one another and can be taken safely on the same day.
Was this helpful?
References
1.-
Shah N, Gossman W. Omeprazole. 2023 Feb 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30969608. https://www.ncbi.nlm.nih.gov/books/NBK539786
2.-
Nguyen K, Dersnah GD, Ahlawat R. Famotidine. 2022 Jul 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30521199. https://www.ncbi.nlm.nih.gov/books/NBK534778
3.-
Mann SG, Murakami A, McCarroll K, Rao AN, Cottrell J, Mehentee J, Morton R. Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal. Aliment Pharmacol Ther. 1995 Aug;9(4):395-401. doi: 10.1111/j.1365-2036.1995.tb00397.x. PMID: 8527615. https://pubmed.ncbi.nlm.nih.gov/8527615/
4.-
Savarino V, Picciotto A, Magnolia MR, Scalabrini P, Mela GS, Celle G. Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring. J Clin Pharmacol. 1987 Oct;27(10):790-3. doi: 10.1002/j.1552-4604.1987.tb02998.x. PMID: 2892864. https://pubmed.ncbi.nlm.nih.gov/2892864/
5.-
Parikh NS, Ahlawat R. Helicobacter Pylori. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30480966. https://www.ncbi.nlm.nih.gov/books/NBK534233
